SCTX - Latest News
Scribe Therapeutics Inc. (SCTX), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $309.4M. Beta to the broader market is 0.00.
The article list below shows the most recent SCTX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent SCTX Headlines
Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts
defenseworld.net - Sep 28, 2026
Scribe Therapeutics Inc. (NASDAQ: SCTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com - Sep 2, 2026
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing techn
Scribe Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com - Sep 1, 2026
ALAMEDA, Calif. , Sept.
Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More
247wallst.com - Aug 31, 2026
Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
globenewswire.com - Jul 27, 2026
ALAMEDA, Calif. , July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc.
How News Affects SCTX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track SCTX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked SCTX news questions
- What is the latest SCTX news headline?
- The most recent SCTX headline (Sep 28, 2026) is "Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the SCTX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What SCTX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual SCTX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.